{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T09:11:23Z","timestamp":1764493883241},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2015,7,6]],"date-time":"2015-07-06T00:00:00Z","timestamp":1436140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,7,6]],"date-time":"2015-07-06T00:00:00Z","timestamp":1436140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1038\/bmt.2015.156","type":"journal-article","created":{"date-parts":[[2015,7,6]],"date-time":"2015-07-06T15:27:39Z","timestamp":1436196459000},"page":"1293-1298","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Non-myeloablative allogeneic hematopoietic stem cell transplantation for adults with relapsed and refractory mantle cell lymphoma: a single-center analysis in the rituximab era"],"prefix":"10.1038","volume":"50","author":[{"given":"A","family":"Mussetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S M","family":"Devlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H R","family":"Castro-Malaspina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J N","family":"Barker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S A","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A D","family":"Zelenetz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C S","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M-A","family":"Perales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,7,6]]},"reference":[{"key":"BFbmt2015156_CR1","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2141.2010.08228.x","volume":"150","author":"JE Romaguera","year":"2010","unstructured":"Romaguera JE, Fayad LE, Feng L, Hartig K, Weaver P, Rodriguez MA et al. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate\/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 2010; 150: 200\u2013208.","journal-title":"Br J Haematol"},{"key":"BFbmt2015156_CR2","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1046\/j.1365-2141.2003.04140.x","volume":"120","author":"E Vandenberghe","year":"2003","unstructured":"Vandenberghe E, Ruiz de Elvira C, Loberiza FR, Conde E, Lopez-Guillermo A, Gisselbrecht C et al. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol 2003; 120: 793\u2013800.","journal-title":"Br J Haematol"},{"key":"BFbmt2015156_CR3","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1365-2141.2012.09174.x","volume":"158","author":"CH Geisler","year":"2012","unstructured":"Geisler CH, Kolstad A, Laurell A, Jerkeman M, Raty R, Andersen NS et al. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol 2012; 158: 355\u2013362.","journal-title":"Br J Haematol"},{"key":"BFbmt2015156_CR4","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1182\/blood-2002-08-2476","volume":"102","author":"AM Gianni","year":"2003","unstructured":"Gianni AM, Magni M, Martelli M, Di Nicola M, Carlo-Stella C, Pilotti S et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 2003; 102: 749\u2013755.","journal-title":"Blood"},{"key":"BFbmt2015156_CR5","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","volume":"26","author":"KS Robinson","year":"2008","unstructured":"Robinson KS, Williams ME, van der Jagt RH, Cohen P, Herst JA, Tulpule A et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008; 26: 4473\u20134479.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015156_CR6","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","volume":"24","author":"RI Fisher","year":"2006","unstructured":"Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006; 24: 4867\u20134874.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015156_CR7","doi-asserted-by":"publisher","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","volume":"31","author":"A Goy","year":"2013","unstructured":"Goy A, Sinha R, Williams ME, Kalayoglu Besisik S, Drach J, Ramchandren R et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol 2013; 31: 3688\u20133695.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015156_CR8","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369: 507\u2013516.","journal-title":"N Engl J Med"},{"key":"BFbmt2015156_CR9","doi-asserted-by":"publisher","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","volume":"27","author":"G Hess","year":"2009","unstructured":"Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27: 3822\u20133829.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015156_CR10","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1200\/JCO.2012.46.9585","volume":"31","author":"FA Morschhauser","year":"2013","unstructured":"Morschhauser FA, Cartron G, Thieblemont C, Solal-Celigny P, Haioun C, Bouabdallah R et al. Obinutuzumab (GA101) monotherapy in relapsed\/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J Clin Oncol 2013; 31: 2912\u20132919.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015156_CR11","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1182\/blood-2011-10-387969","volume":"119","author":"BG Till","year":"2012","unstructured":"Till BG, Jensen MC, Wang J, Qian X, Gopal AK, Maloney DG et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 2012; 119: 3940\u20133950.","journal-title":"Blood"},{"key":"BFbmt2015156_CR12","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.blre.2014.10.001","volume":"29","author":"A Mussetti","year":"2014","unstructured":"Mussetti A, Kumar A, Dahi PB, Perales MA, Sauter CS . Lifting the mantle: unveiling new treatment approaches in relapsed or refractory mantle cell lymphoma. Blood Rev 2014; 29: 143\u2013152.","journal-title":"Blood Rev"},{"key":"BFbmt2015156_CR13","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1093\/annonc\/mdu097","volume":"25","author":"S Dietrich","year":"2014","unstructured":"Dietrich S, Boumendil A, Finel H, Avivi I, Volin L, Cornelissen J et al. Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol 2014; 25: 1053\u20131058.","journal-title":"Ann Oncol"},{"key":"BFbmt2015156_CR14","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1023\/A:1008380527502","volume":"10","author":"IF Khouri","year":"1999","unstructured":"Khouri IF, Lee MS, Romaguera J, Mirza N, Kantarjian H, Korbling M et al. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy. Ann Oncol 1999; 10: 1293\u20131299.","journal-title":"Ann Oncol"},{"key":"BFbmt2015156_CR15","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1182\/blood.V98.13.3595","volume":"98","author":"IF Khouri","year":"2001","unstructured":"Khouri IF, Saliba RM, Giralt SA, Lee MS, Okoroji GJ, Hagemeister FB et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001; 98: 3595\u20133599.","journal-title":"Blood"},{"key":"BFbmt2015156_CR16","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1182\/blood-2008-03-077974","volume":"112","author":"HJ Kolb","year":"2008","unstructured":"Kolb HJ . Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008; 112: 4371\u20134383.","journal-title":"Blood"},{"key":"BFbmt2015156_CR17","doi-asserted-by":"crossref","unstructured":"Khouri IF . Reduced-intensity regimens in allogeneic stem-cell transplantation for non-hodgkin lymphoma and chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2006: 390\u2013397.","DOI":"10.1182\/asheducation-2006.1.390"},{"key":"BFbmt2015156_CR18","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/leu.2014.223","volume":"29","author":"S Robinson","year":"2015","unstructured":"Robinson S, Dreger P, Caballero D, Corradini P, Geisler C, Ghielmini M et al. The EBMT\/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma. Leukemia 2015; 29: 464\u2013473.","journal-title":"Leukemia"},{"key":"BFbmt2015156_CR19","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1093\/annonc\/mds054","volume":"23","author":"S Le Gouill","year":"2012","unstructured":"Le Gouill S, Kroger N, Dhedin N, Nagler A, Bouabdallah K, Yakoub-Agha I et al. Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed\/refractory mantle cell lymphoma: a multicenter experience. Ann Oncol 2012; 23: 2695\u20132703.","journal-title":"Ann Oncol"},{"key":"BFbmt2015156_CR20","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/j.bbmt.2010.04.006","volume":"16","author":"G Cook","year":"2010","unstructured":"Cook G, Smith GM, Kirkland K, Lee J, Pearce R, Thomson K et al. Outcome following reduced-intensity allogeneic stem cell transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2010; 16: 1419\u20131427.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2015156_CR21","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1200\/JCO.2013.49.2454","volume":"32","author":"TS Fenske","year":"2014","unstructured":"Fenske TS, Zhang MJ, Carreras J, Ayala E, Burns LJ, Cashen A et al. Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality. J Clin Oncol 2014; 32: 273\u2013281.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015156_CR22","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2013.01.009","volume":"19","author":"M Hamadani","year":"2013","unstructured":"Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS et al. Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant 2013; 19: 625\u2013631.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2015156_CR23","doi-asserted-by":"publisher","first-page":"4144","DOI":"10.1182\/blood-2008-10-184200","volume":"113","author":"CS Tam","year":"2009","unstructured":"Tam CS, Bassett R, Ledesma C, Korbling M, Alousi A, Hosing C et al. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 2009; 113: 4144\u20134152.","journal-title":"Blood"},{"key":"BFbmt2015156_CR24","doi-asserted-by":"publisher","first-page":"4150","DOI":"10.1200\/JCO.2006.06.9914","volume":"24","author":"F Baron","year":"2006","unstructured":"Baron F, Storb R, Storer BE, Maris MB, Niederwieser D, Shizuru JA et al. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. J Clin Oncol 2006; 24: 4150\u20134157.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015156_CR25","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1007\/s00277-014-2087-z","volume":"93","author":"WH Kruger","year":"2014","unstructured":"Kruger WH, Hirt C, Basara N, Sayer HG, Behre G, Fischer T et al. Allogeneic stem cell transplantation for mantle cell lymphoma\u2014final report from the prospective trials of the East German Study Group Haematology\/Oncology (OSHO). Ann Hematol 2014; 93: 1587\u20131597.","journal-title":"Ann Hematol"},{"key":"BFbmt2015156_CR26","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1182\/blood-2010-04-280966","volume":"117","author":"JN Barker","year":"2011","unstructured":"Barker JN, Byam C, Scaradavou A . How I treat: the selection and acquisition of unrelated cord blood grafts. Blood 2011; 117: 2332\u20132339.","journal-title":"Blood"},{"key":"BFbmt2015156_CR27","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.bbmt.2013.11.029","volume":"20","author":"CS Sauter","year":"2014","unstructured":"Sauter CS, Barker JN, Lechner L, Zheng J, Devlin SM, Papadopoulos EB et al. A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients. Biol Blood Marrow Transplant 2014; 20: 354\u2013360.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2015156_CR28","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.3109\/10428194.2014.894185","volume":"55","author":"CS Sauter","year":"2014","unstructured":"Sauter CS, Chou JF, Papadopoulos EB, Perales MA, Jakubowski AA, Young JW et al. A prospective study of an alemtuzumab containing reduced-intensity allogeneic stem cell transplant program in patients with poor-risk and advanced lymphoid malignancies. Leuk Lymphoma 2014; 55: 2739\u20132747.","journal-title":"Leuk Lymphoma"},{"key":"BFbmt2015156_CR29","doi-asserted-by":"publisher","first-page":"663","DOI":"10.3109\/10428194.2014.930851","volume":"56","author":"I Ceberio","year":"2015","unstructured":"Ceberio I, Devlin SM, Sauter C, Barker JN, Castro-Malaspina H, Giralt S et al. Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant. Leuk Lymphoma 2015; 56: 663\u2013670.","journal-title":"Leuk Lymphoma"},{"key":"BFbmt2015156_CR30","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.bbmt.2013.02.007","volume":"19","author":"DM Ponce","year":"2013","unstructured":"Ponce DM, Sauter C, Devlin S, Lubin M, Gonzales AM, Kernan NA et al. A novel reduced-intensity conditioning regimen induces a high incidence of sustained donor-derived neutrophil and platelet engraftment after double-unit cord blood transplantation. Biol Blood Marrow Transplant 2013; 19: 799\u2013803.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2015156_CR31","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","volume":"111","author":"E Hoster","year":"2008","unstructured":"Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008; 111: 558\u2013565.","journal-title":"Blood"},{"key":"BFbmt2015156_CR32","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/bmt.2009.371","volume":"45","author":"MA Perales","year":"2010","unstructured":"Perales MA, Jenq R, Goldberg JD, Wilton AS, Lee SS, Castro-Malaspina HR et al. Second-line age-adjusted International Prognostic Index in patients with advanced non-Hodgkin lymphoma after T-cell depleted allogeneic hematopoietic SCT. Bone Marrow Transplant 2010; 45: 1408\u20131416.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015156_CR33","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/sj.bmt.1701624","volume":"23","author":"CH Moskowitz","year":"1999","unstructured":"Moskowitz CH, Nimer SD, Glassman JR, Portlock CS, Yahalom J, Straus DJ et al. The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma. Bone Marrow Transplant 1999; 23: 561\u2013567.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015156_CR34","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/j.bbmt.2013.07.005","volume":"19","author":"RD Cassaday","year":"2013","unstructured":"Cassaday RD, Guthrie KA, Budde EL, Thompson L, Till BG, Press OW et al. Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2013; 19: 1403\u20131406.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2015156_CR35","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579\u2013586.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015156_CR36","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1046\/j.1365-2141.1997.1112925.x","volume":"97","author":"PA Rowlings","year":"1997","unstructured":"Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, Henslee-Downey PJ et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 1997; 97: 855\u2013864.","journal-title":"Br J Haematol"},{"key":"BFbmt2015156_CR37","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945\u2013956.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2015156_CR38","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1182\/blood-2004-03-1105","volume":"104","author":"E Morris","year":"2004","unstructured":"Morris E, Thomson K, Craddock C, Mahendra P, Milligan D, Cook G et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004; 104: 3865\u20133871.","journal-title":"Blood"},{"key":"BFbmt2015156_CR39","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1182\/blood-2002-03-0701","volume":"100","author":"JA Perez-Simon","year":"2002","unstructured":"Perez-Simon JA, Kottaridis PD, Martino R, Craddock C, Caballero D, Chopra R et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 2002; 100: 3121\u20133127.","journal-title":"Blood"},{"key":"BFbmt2015156_CR40","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood.V100.5.1715.h81702001715_1715_1720","volume":"100","author":"AG Buggins","year":"2002","unstructured":"Buggins AG, Mufti GJ, Salisbury J, Codd J, Westwood N, Arno M et al. Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Blood 2002; 100: 1715\u20131720.","journal-title":"Blood"},{"key":"BFbmt2015156_CR41","first-page":"713","volume":"18","author":"R Condiotti","year":"1996","unstructured":"Condiotti R, Nagler A . Campath-1G impairs human natural killer (NK) cell-mediated cytotoxicity. Bone Marrow Transplant 1996; 18: 713\u2013720.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015156_CR42","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1126\/science.1068440","volume":"295","author":"L Ruggeri","year":"2002","unstructured":"Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097\u20132100.","journal-title":"Science"},{"key":"BFbmt2015156_CR43","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1182\/blood-2013-08-519199","volume":"123","author":"HE Kohrt","year":"2014","unstructured":"Kohrt HE, Thielens A, Marabelle A, Sagiv-Barfi I, Sola C, Chanuc F et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood 2014; 123: 678\u2013686.","journal-title":"Blood"},{"key":"BFbmt2015156_CR44","doi-asserted-by":"publisher","first-page":"3108","DOI":"10.1182\/blood-2002-02-0506","volume":"100","author":"DI Marks","year":"2002","unstructured":"Marks DI, Lush R, Cavenagh J, Milligan DW, Schey S, Parker A et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 2002; 100: 3108\u20133114.","journal-title":"Blood"},{"key":"BFbmt2015156_CR45","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.1182\/blood-2003-04-1205","volume":"102","author":"K van Besien","year":"2003","unstructured":"van Besien K, Loberiza FR Jr., Bajorunaite R, Armitage JO, Bashey A, Burns LJ et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003; 102: 3521\u20133529.","journal-title":"Blood"},{"key":"BFbmt2015156_CR46","first-page":"669","volume":"18","author":"G Rondon","year":"1996","unstructured":"Rondon G, Giralt S, Huh Y, Khouri I, Andersson B, Andreeff M et al. Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant 1996; 18: 669\u2013672.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015156_CR47","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1200\/JCO.2003.12.011","volume":"21","author":"J Schetelig","year":"2003","unstructured":"Schetelig J, Thiede C, Bornhauser M, Schwerdtfeger R, Kiehl M, Beyer J et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol 2003; 21: 2747\u20132753.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015156_CR48","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/1096-8652(200009)65:1<75::AID-AJH14>3.0.CO;2-L","volume":"65","author":"SK Sohn","year":"2000","unstructured":"Sohn SK, Baek JH, Kim DH, Jung JT, Kwak DS, Park SH et al. Successful allogeneic stem-cell transplantation with prophylactic stepwise G-CSF primed-DLIs for relapse after autologous transplantation in mantle cell lymphoma: a case report and literature review on the evidence of GVL effects in MCL. Am J Hematol 2000; 65: 75\u201380.","journal-title":"Am J Hematol"},{"key":"BFbmt2015156_CR49","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1038\/sj.leu.2404822","volume":"21","author":"P Corradini","year":"2007","unstructured":"Corradini P, Dodero A, Farina L, Fanin R, Patriarca F, Miceli R et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia 2007; 21: 2316\u20132323.","journal-title":"Leukemia"},{"key":"BFbmt2015156_CR50","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/sj.bmt.1701540","volume":"23","author":"A Grigg","year":"1999","unstructured":"Grigg A, Bardy P, Byron K, Seymour JF, Szer J . Fludarabine-based non-myeloablative chemotherapy followed by infusion of HLA-identical stem cells for relapsed leukaemia and lymphoma. Bone Marrow Transplant 1999; 23: 107\u2013110.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015156_CR51","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1182\/blood-2012-09-458570","volume":"122","author":"A Urbano Ispizua","year":"2013","unstructured":"Urbano Ispizua A, Pavletic SZ, Flowers MED, Zhang M-J, Carreras J, Smith SM et al. Association of graft vs. host disease (GVHD) with a lower relapse\/progression rate after allogeneic hemopoietic stem cell transplantation (HSCT) with reduced intensity conditioning in patients with follicular and mantle cell lymphoma: a Cibmtr analysis. Blood 2013; 122: 2093\u20132093.","journal-title":"Blood"},{"key":"BFbmt2015156_CR52","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.bbmt.2014.02.009","volume":"20","author":"CS Sauter","year":"2014","unstructured":"Sauter CS, Lechner L, Scordo M, Zheng J, Devlin SM, Fleming SE et al. Pretransplantation fluorine-18-deoxyglucose-positron emission tomography scan lacks prognostic value in chemosensitive B cell non-Hodgkin lymphoma patients undergoing nonmyeloablative allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2014; 20: 881\u2013884.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2015156_CR53","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","volume":"363","author":"TA Gooley","year":"2010","unstructured":"Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010; 363: 2091\u20132101.","journal-title":"N Engl J Med"},{"key":"BFbmt2015156_CR54","doi-asserted-by":"publisher","first-page":"802","DOI":"10.3109\/10428194.2013.815349","volume":"55","author":"D Salek","year":"2014","unstructured":"Salek D, Vesela P, Boudova L, Janikova A, Klener P, Vokurka S et al. Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database. Leuk Lymphoma 2014; 55: 802\u2013810.","journal-title":"Leuk Lymphoma"},{"key":"BFbmt2015156_CR55","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/j.1365-2141.2005.05716.x","volume":"131","author":"M Tiemann","year":"2005","unstructured":"Tiemann M, Schrader C, Klapper W, Dreyling MH, Campo E, Norton A et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol 2005; 131: 29\u201338.","journal-title":"Br J Haematol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2015156.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2015156","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2015156.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T21:37:53Z","timestamp":1717969073000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2015156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,6]]},"references-count":55,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["BFbmt2015156"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2015.156","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,6]]},"assertion":[{"value":"18 December 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AM was supported in part by the Associazione Italiana Contro le Leucemie-Linfomi e Mieloma ONLUS. SMD, HC-M, JNB, SG, ADZ, CSS and MAP have nothing to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}